Future oncology (London, England) · 2025
Epidemiology, resource use, and treatment patterns of locally advanced or metastatic urothelial carcinoma in France.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Joly Florence, Culine Stephane, Roupret Morgan, Tricotel Aurore, Casarotto Emilie, Brice Sandrine, Minacori Rafael, Vuillet Marthe, Thomas Marie-Catherine, Leyland Kirsten, Upadhyay Anil, Munro Vicki, Strunz-McKendry Torsten
Аннотация
AIM: Describe real-world epidemiology, treatment patterns, health care resource utilization, and costs of locally advanced or metastatic urothelial carcinoma (la/mUC) in France.
PATIENTS & METHODS: Retrospective study including all adults with la/mUC diagnosis during January 2017 to December 2020 in the PMSI database.
RESULTS: Annual prevalence and incidence ranged from 36.4 to 38.9 and 16.4 to 18.5 cases per 100,000 people, respectively. Of the 25,314 patients with incident la/mUC, 37.6% did not receive first-line systemic treatment. Of the 14,656 patients who started first-line systemic treatment, 66.6%, 22.5%, and 10.9% received 1, 2, and 3 lines of therapy, respectively. Annual per-patient costs in second-/third-line setting ranged from €8803 to €16,012.
CONCLUSION: The substantial disease burden of la/mUC in France highlights the unmet need for new therapies.
PATIENTS & METHODS: Retrospective study including all adults with la/mUC diagnosis during January 2017 to December 2020 in the PMSI database.
RESULTS: Annual prevalence and incidence ranged from 36.4 to 38.9 and 16.4 to 18.5 cases per 100,000 people, respectively. Of the 25,314 patients with incident la/mUC, 37.6% did not receive first-line systemic treatment. Of the 14,656 patients who started first-line systemic treatment, 66.6%, 22.5%, and 10.9% received 1, 2, and 3 lines of therapy, respectively. Annual per-patient costs in second-/third-line setting ranged from €8803 to €16,012.
CONCLUSION: The substantial disease burden of la/mUC in France highlights the unmet need for new therapies.